Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07435012 TH-07 Androgenetic Alopecia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07435012 clinical trial report covering TH-07, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07434973 Cannabidiol Bipolar I disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07434973 clinical trial report covering Cannabidiol, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260731 Urea-13C Helicobacter pylori infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260731 clinical trial report covering Urea-13C, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07435051 Vancomycin Hydrochloride Osteomyelitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07435051 clinical trial report covering Vancomycin Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260675 UREA, C-14 Helicobacter pylori infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260675 clinical trial report covering UREA, C-14, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07443397 Anlotinib Dihydrochloride Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07443397 clinical trial report covering Anlotinib Dihydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07442513 Etamsylate Hemorrhage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07442513 clinical trial report covering Etamsylate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07443163 Dexmedetomidine Hydrochloride Reversal of Neuromuscular Blockade Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07443163 clinical trial report covering Dexmedetomidine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07444086 RBD-7022 Mixed hyperlipidemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07444086 clinical trial report covering RBD-7022, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07441460 Anbenitamab HER2 Positive Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07441460 clinical trial report covering Anbenitamab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260268 Budesonide/Formoterol Fumarate Dihydrate Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260268 clinical trial report covering Budesonide/Formoterol Fumarate Dihydrate, Phase 3, endpoints, sponsor, geography, readout timing and development
Latest Hotspot
8 min read
NCT07442565 SYS-6010 Non-squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07442565 clinical trial report covering SYS-6010, Phase 3, endpoints, sponsor, geography, readout timing and development white space.